CLMN

Across TCGA pan-cancer cohorts, CLMN mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CLMN data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLMN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLMN expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where CLMN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.614	0.268	<.001	71	view →
CCRCC	DFS	Tertile	III,IV	0.753	0.342	.002	22	view →
UCEC	DFS	Tertile	II,III,IV	0.904	0.422	.031	4	view →
LUAD	OS	Median	III,IV	0.333	0.897	.013	4	view →
HNSC	OS	Median	All	0.943	0.987	.036	3	view →
GBM	DFS	Tertile	All	0.298	0.433	.033	2	view →
LSCC	DFS	Median	All	0.867	0.736	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CLMN–PDAC (OS)

Open the PDAC breakdown →